Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (11-20 of 194) with videos related to

Pageof 20
Sort By:
International Journal of Hematology|November 15, 2002
Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISHBart Barlogie, John D Shaughnessy
International Journal of Hematology|November 15, 2002
Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myelomaJohn D Shaughnessy, Bart Barlogie
Immunological Reviews|July 9, 2003
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profilingJohn D Shaughnessy, Bart Barlogie
Journal of Cellular Biochemistry|January 28, 2006
Role of osteoblast suppression in multiple myelomaJames Peter Stewart, John D Shaughnessy
Seminars in Hematology|June 26, 2012
Proteasome inhibitors: introductionChristoph J Heuck, John D Shaughnessy
The New England Journal of Medicine|July 11, 2008
Duration of survival in patients with myeloma treated with thalidomideBart Barlogie, John D Shaughnessy, John Crowley
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2007
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathwayJürgen Knobloch, John D Shaughnessy, Ulrich Rüther
Blood|November 8, 2008
Going with the flow, and beyond, in myelomaBart Barlogie, Joshua Epstein, John D Shaughnessy
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Leukemia|August 7, 2009
The molecular characterization and clinical management of multiple myeloma in the post-genome eraY Zhou, B Barlogie, J D Shaughnessy
Pageof 20

Showing results (11-20 of 194) with videos related to

Sort By:
Pageof 20
International Journal of Hematology|November 15, 2002
Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISHBart Barlogie, John D Shaughnessy
International Journal of Hematology|November 15, 2002
Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myelomaJohn D Shaughnessy, Bart Barlogie
Immunological Reviews|July 9, 2003
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profilingJohn D Shaughnessy, Bart Barlogie
Journal of Cellular Biochemistry|January 28, 2006
Role of osteoblast suppression in multiple myelomaJames Peter Stewart, John D Shaughnessy
Seminars in Hematology|June 26, 2012
Proteasome inhibitors: introductionChristoph J Heuck, John D Shaughnessy
The New England Journal of Medicine|July 11, 2008
Duration of survival in patients with myeloma treated with thalidomideBart Barlogie, John D Shaughnessy, John Crowley
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2007
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathwayJürgen Knobloch, John D Shaughnessy, Ulrich Rüther
Blood|November 8, 2008
Going with the flow, and beyond, in myelomaBart Barlogie, Joshua Epstein, John D Shaughnessy
The New England Journal of Medicine|September 26, 2008
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2Bart Barlogie, John D Shaughnessy, John Crowley
Leukemia|August 7, 2009
The molecular characterization and clinical management of multiple myeloma in the post-genome eraY Zhou, B Barlogie, J D Shaughnessy
Pageof 20